

Bibliografía

1. Llor C, Hernández S. Enfermedad infecciosa en atención primaria: estudio prospectivo efectuado durante un año. *Enferm Infect Microbiol Clin.* 2010;28:222-6.
2. Arroll B, Kenealy T. Antibiotics for the common cold and acute purulent rhinitis. *Cochrane Database Syst Rev.* 2005;(3):CD000247.
3. Spinks A, Glasziou PP, Del Mar CB. Antibiotics for sore throat. *Cochrane Database Syst Rev.* 2010;(3):CD000023.
4. Smucny J, Fahey T, Becker L, Glazier R. Antibiotics for acute bronchitis. *Cochrane Database Syst Rev.* 2004;(4):CD000245.
5. Glasziou PP, Del Mar CB, Sanders SL, Hayem M. Treatment for acute otitis media in children. *Cochrane Database Syst Rev.* 2004;(1):CD000219.
6. Young J, De Sutter A, Merenstein D, van Essen GA, Kaiser L, Varonen H, et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data. *Lancet.* 2008;371:908-14.
7. Llor C, Cots JM, Bjerrum L, Cid M, Guerra G, Arranz X, et al; y grupo de estudio Happy Audit España. Prescripción de antibióticos en las infecciones del tracto respiratorio y factores predictores de su utilización. *Aten Primaria.* 2010;42:28-35.
8. Palop V, Melchor A, Martínez Mir I. Reflexiones sobre la utilización de antibióticos en atención primaria. *Aten Primaria.* 2003;32:42-7.
9. Cots JM, Monedero J, Arranz J, Gómez M, Mórato ML, Sánchez C (editores). Manual de enfermedades infecciosas en Atención Primaria 3.^a ed. Barcelona: semFYC Ediciones; 2010.
10. Butler CC, Rollnick S, Kinnersley P, Jones A, Stott NCH. Reducing antibiotics for respiratory tract symptoms in primary care; consolidating 'why' and considering 'how'. *Br J Gen Pract.* 1998;48:1865-70.
11. Little PS, Gould C, Williamson I, Warner G, Gantley M, Kinmonth AL. Reattendance and complications in a randomised trial of prescribing strategies for sore throat: the medicalising effect of prescribing antibiotics. *BMJ.* 1997;315:350-2.
12. ECDC/EMEA Joint Working Group. The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. Estocolmo: European Centre for Disease Prevention and Control, 2009. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2009/11/WC500008770.pdf
13. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis.* 2009;48:1-12.
14. Butler CC, Rollnick S, Maggs-Rapport F, Pill RM, Stott N. Understanding the culture of prescribing: qualitative study of general practitioners' and patients' perceptions of antibiotics for sore throats. *BMJ.* 1998;317:637-42.
15. Agencia Española de Medicamentos y Productos Sanitarios y Dirección General de Farmacia y Productos Sanitarios. Uso de antibióticos en España. Ministerio de Sanidad, Política Social e Igualdad, 2010. Disponible en: www.aemps.es/profHumana/observatorio/docs/antibioticos.pdf
16. Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *Lancet.* 2005;365:579-87.
17. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. *BMJ.* 2010;340:c2096.
18. Pérez-Trallero E, Herrero JE, Mazón A, García-Delafuente C, Robles P, Iriarte V, et al. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). *Antimicrob Agents Chemother.* 2010;54:2953-9.
19. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. *J Allergy Clin Immunol.* 2010;125(Suppl 2):S103-15.
20. Thomas M, Yawn BP, Price D, Lund V, Mullol J, Fokkens W, on behalf of the European Position Paper on Rhinosinusitis and Nasal Polyps Group. EPOS primary care guidelines: European position paper on the primary care diagnosis and management of rhinosinusitis and nasal polyps 2007 - a summary. *Prim Care Respir J.* 2008;17:79-89.
21. Osguthorpe J, Hadley J. Rhinosinusitis, current concepts in evaluation and management. *Med Clin North Am.* 1999;83:27-41.
22. Hansen JG, Schmidt H, Rosborg J, Lund E. Predicting acute maxillary sinusitis in a general practice population. *BMJ.* 1995;311:233-6.
23. Singh M. Heated, humidified air for the common cold. *Cochrane Database Syst Rev.* 2004;(2):CD001728.
24. D'Cruze H, Arroll B, Kenealy T. Is intranasal zinc effective and safe for the common cold? A systematic review and meta-analysis. *J Prim Health Care.* 2009;1:134-9.
25. Zalmanovici A, Yaphé J. Intranasal steroids for acute sinusitis. *Cochrane Database Syst Rev.* 2009;(4):CD005149.
26. Falagas ME, Giannopoulou KP, Vardakas KZ, Dimopoulos G, Karageorgopoulos DE. Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised controlled trials. *Lancet Infect Dis.* 2008;8:543-52.
27. Williams JW, Aguilar C, Cornell J, Chiquette ED, Makela M, Holleman DR, et al. Antibiotics for acute maxillary sinusitis. *Cochrane Database Syst Rev.* 2003;2:CD000243.
28. Babar-Craig H, Gupta Y, Lund VJ. British Rhinological Society audit of the role of antibiotics in complications of acute rhinosinusitis: a national prospective audit. *Rhinology.* 2010;48:344-7.
29. Morris P, Leach A. Antibiotics for persistent nasal discharge (rhino-sinusitis) in children. *Cochrane Database Syst Rev.* 2002;4: CD001094.
30. Healthcare Infection Control Practices Advisory Committee, HICPAC/SHEA/APIC/ IDSA Hand Hygiene Task Force. Guideline for hand hygiene in health-care settings. *MMWR.* 2002;51(RR-16):1-48.
31. Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux RA, et al. Antibiotics for acute otitis media: a meta-analysis with individual patient data. *Lancet.* 2006;368:1429-35.
32. Rosenfeld RM, Vertrees JE, Carr J, Cipolle RJ, Uden DL, Giebink GS, Canafax DM. Clinical efficacy of antimicrobial drugs for acute otitis media: Metaanalysis of 5400 children from thirty-three randomized trials. *J Pediatr.* 1994;124:355-6.
33. Arason VA, Sigurdsson JA, Kristinsson KG, Getz L, Gudmundsson S. Otitis media, tympanostomy tube placement, and use of antibiotics. *Scand J Prim Health Care.* 2005;23:184-91.
34. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. *Pediatrics.* 2004;113:1451-65.
35. Hoberman A, Paradise JL, Rockette HE, Shaikh N, Wald ER, Kearney DH, et al. Treatment of acute otitis media in children under 2 years of age. *N Engl J Med.* 2011;364:105-15.
36. Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux RA, et al. Predictors of pain and/or fever at 3 to 7 days for children with acute otitis media not treated initially with antibiotics: a meta-analysis of individual patient data. *Pediatrics.* 2007;119:579-85.
37. Little P, Gould C, Moore M, Warner G, Dunleavy J, Williamson I. Predictors of poor outcome and benefits from antibiotics in children with acute otitis media: pragmatic randomised trial. *BMJ.* 2002;325:22-4.
38. Little P, Moore M, Warner G, Dunleavy J, Williamson I. Longer term outcomes from a randomised trial of prescribing strategies in otitis media. *Br J Gen Pract.* 2006;56:176-82.
39. Christian-Kopp S, Sinha M, Rosenberg DJ, Eisenhart AW, McDonald FW. Antibiotic dosing for acute otitis media in children: a weighty issue. *Pediatr Emerg Care.* 2010;26:19-25.
40. Coleman C, Moore M. Decongestants and antihistamines for acute otitis media in children. *Cochrane Database Syst Rev.* 2008;(3): CD001727.

41. Neuner JM, Hamel MB, Phillips RS, Bona K, Aronson MD. Diagnosis and management of adults with pharyngitis. A cost-effectiveness analysis. *Ann Intern Med.* 2003;139:113-22.
42. Cooper RJ, Hoffman JR, Bartlett JG et al; Centers for Disease Control and Prevention. Principles of appropriate antibiotic use for acute pharyngitis in adults: background. *Ann Intern Med.* 2001;134: 509-17.
43. Centor RM. Expand the pharyngitis paradigm for adolescents and young adults. *Ann Intern Med.* 2009;151:812-5.
44. Petersen I, Johnson AM, Islam A, Duckworth G, Livermore DM, Hayward AC. Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database. *BMJ.* 2007; 335:982.
45. Centor RM, Whitterspoon JM, Dalton HP, Brody CE, Link K. The diagnosis of strep throat in adults in the emergency room. *Med Decis Making.* 1981;1:239-46.
46. McIsaac WJ, Kellner J, Aufricht P, Vanjaka A, Low DE. Empirical validation of guidelines for the management of pharyngitis in children and adults. *JAMA.* 2004;291:1587-95.
47. Llor C, Hernández S, Gómez FF, Santamaría JM, Calviño O, Fernández Y. Validación de una técnica antigenica rápida en el diagnóstico de la faringitis por estreptococo betahemolítico del grupo A. *Aten Primaria.* 2008;40:489-94.
48. Bisno AL, Gerber MA, Gwaltney JM, Kaplan EL, Schwartz RH. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. *Clin Infect Dis.* 2002;35:113-25.
49. Llor C. Un test rápido de detección de antígenos del estreptococo β-hemolítico del grupo A (Strep A). *AMF.* 2010;6:429-33.
50. van Driel ML, De Sutter AI, Keber N, Hebraken H, Christiaens T. Different antibiotic treatments for group A streptococcal pharyngitis. *Cochrane Database Syst Rev.* 2010;(10):CD004406.
51. Lan AJ, Colford JM. The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: a meta-analysis. *Pediatrics.* 2000;105:1-8.
52. Fyllingen G, Arnesen AR, Biermann C, Kaarby O, Romfo O, Rønnevig J, et al. Phenoxymethylpenicillin two or three times daily for tonsillitis with beta-haemolytic streptococci group A: a blinded, randomized and controlled clinical study. *Scand J Infect Dis.* 1991;23:553-8.
53. Marshall T. A review of tonsillectomy for recurrent throat infection. *Br J Gen Pract.* 1998;48:1331-5.
54. Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses. *Am J Med.* 2007;120:911.e1-8.
55. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR Recomm Rep.* 2010 Aug 6;59(RR-8):1-62.
56. Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during the influenza season. *Clin Infect Dis.* 2006;43:564-8.
57. Stein J, Louie J, Flanders S, Maselli J, Hacker JK, Drew WL, Gonzales R. Performance characteristics of clinical diagnosis, a clinical decision rule, and a rapid influenza test in the detection of influenza infection in a community sample of adults. *Ann Emerg Med.* 2005; 46:412-9.
58. Stanley ED, Jackson GG, Panusarn C, Rubenis M, Dirda V. Increased virus shedding with aspirin treatment of rhinovirus infection. *JAMA.* 1975;231:1248-51.
59. Millet VM, Dreisbach M, Bryson YJ. Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine. *Antimicrobial Agents Chemother.* 1982;21:1-4.
60. Bright RA, Medina MJ, Xu X, Pérez-Oronoz G, Wallis TR, Davis XM, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. *Lancet.* 2005;366:1175-81.
61. Moscona A. Neuraminidase inhibitors for influenza. *N Engl J Med.* 2005;353:1363-73.
62. Sepkowitz KA. Forever unprepared – The predictable unpredictability of pathogens. *N Engl J Med.* 2009;361:120-1.
63. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev.* 2010;(7):CD001269.
64. Diehr P, Wood RW, Bushyhead J, Krueger L, Walcott B, Tompkins RK. Prediction of pneumonia in outpatients with acute cough a statistical approach. *J Chronic Dis.* 1984;37:215-25.
65. Melbye H, Straume B, Aasebø U, Dale K. Diagnosis of pneumonia in adults in general practice. Relative importance of typical symptoms and abnormal chest signs evaluated against a radiographic reference standard. *Scand J Prim Health Care.* 1992;10:226-33.
66. González Ortiz MA, Carnicer Bujarrabal M, Varela Entrecanales M. Predicción de la presencia de neumonía en el adulto con fiebre. *Med Clin (Barc).* 1995;105:521-4.
67. Hopstaken RM, Muris JW, Knottnerus JA, Kester AD, Rinkens PE, Dinant GJ. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. *Br J Gen Pract.* 2003; 53:558-64.
68. Saldías P, Cabrera D, de Solminihac I, Hernández P, Gederlini A, Díaz A. Valor predictivo de la historia clínica y examen físico en el diagnóstico de neumonía del adulto adquirida en la comunidad. *Rev Med Chile.* 2007;135:143-52.
69. Khalil A, Kelen G, Rothman RE. A simple screening tool for identification of community-acquired pneumonia in an inner city emergency department. *Emerg Med J.* 2007;24:336-8.
70. Wipf JE, Lipsky BA, Hirschmann JV, Boyko EJ. Diagnosing pneumonia by physical examination. *Arch Intern Med.* 1999;159:1082-7.
71. Heckerling PS, Tape TG, Wigton RS, Hissong KK, Leikin JB, Ornato JP, et al. Clinical prediction rule for pulmonary infiltrates. *Ann Intern Med.* 1990;113:664-70.
72. Flanders SA, Stein J, Shochat G, Sellers K, Holland M, Maselli J, et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. *Am J Med.* 2004;116:529-35.
73. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. *Am J Med.* 2008;121:219-25.
74. Melbye H, Stocks N. Point of care testing for C-reactive protein. A new path for Australian GPs? *Austr Fam Physician.* 2006;35:513-6.
75. Holm A, Nexoe J, Bistrup LA, Pedersen SS, Obel N, Nielsen LP, Pedersen C. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. *Br J Gen Pract.* 2007;57: 547-54.
76. Patel AR, Hurst JR, Wedzicha JA. The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. *Semin Respir Crit Care Med.* 2010;31:267-75.
77. Stott NC, West RR. Randomised controlled trial of antibiotics in patients with cough and purulent sputum. *Br Med J.* 1976;2:556-9.
78. Cals JW, Scheppers NA, Hopstaken RM, Hood K, Dinant GJ, Goettsch H, et al. Evidence based management of acute bronchitis; sustained competence of enhanced communication skills acquisition in general practice. *Patient Educ Couns.* 2007;68:270-8.
79. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. *Lancet.* 1987;1:671-4.
80. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. *JAMA.* 1996;275:134-41.
81. Santos C, Llorente MA, Carandell E, Gutiérrez M, Riera M, Ramírez A, et al. Lugar de atención, etiología y tratamiento de las neumonías adquiridas en la comunidad de Palma de Mallorca. *Med Clin (Barc).* 1998;110:290-4.

82. Almirall J, Morató I, Riera F, Verdaguer A, Priu R, Coll P, et al. Incidence of community-acquired pneumonia and *Chlamydia pneumoniae* infection: a prospective multicentre study. *Eur Respir J.* 1993;6:14-8.
83. Lieberman D, Shimon A, Shemer-Avni Y, Keren-Naos A, Shtainberg R, Lieberman D. Respiratory viruses in adults with community-acquired pneumonia. *Chest.* 2010;138:811-6.
84. Levy ML, Le Jeune I, Woodhead MA, Macfarlane JT, Lim WS, on behalf of the British Thoracic Society Community Acquired Pneumonia in Adults Guideline Group. Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK. *Prim Care Resp J.* 2010;19:21-7.
85. Mills GD, Oehley MR, Arrol B. Effectiveness of β lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia. A meta-analysis. *BMJ.* 2005;330:456-8.
86. Almirall J, Bolíbar I, Torán P, Pera G, Boquet X, Balanzó X, et al; Community-acquired Pneumonia Maresme Study Group. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. *Chest.* 2004;125:1335-42.
87. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med.* 1997;336:243-50.
88. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax.* 2003;58:377-82.
89. Chalmers JD, Singanayagam A, Akram AR, Mandal P, Short PM, Choudhury G, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. *Thorax.* 2010;65:878-83.
90. Loke YK, Kwok CS, Niruban A, Myint PK. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. *Thorax.* 2010;65:884-90.
91. Vila Córcoles A, Ochoa Gondar O, Rodríguez Blanco T. Utilidad de la escala CRB-65 en la evaluación pronóstica de los pacientes mayores de 65 años con neumonía adquirida en la comunidad. *Med Clin (Barc).* 2010;135:97-102.
92. Pallarés R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. *N Engl J Med.* 1995;333:474-80.
93. Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. *Cochrane Database Syst Rev.* 2009;(4):CD002109.
94. Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. *Clin Infect Dis.* 2010;51:15-22.
95. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. *Eur Respir J.* 2007;29:1224-38.
96. Rohde G, Wiethage A, Borg I, Kauth M, Bauer TT, Gillissen A, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalization – a case-control study. *Thorax.* 2003;58:37-42.
97. Miravitles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M; Study Group of Bacterial Infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. *Chest.* 1999;116:40-6.
98. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2009). Gig Harbor, WA: Medical Communications Resources, Inc; 2009.
99. Decramer M, Miravitles M, Price D, Román-Rodríguez M, Llor C, Welte T, et al. New horizons in early stage COPD – Improving knowledge, detection and treatment. *Respir Med.* 2011. doi:10.1016/j.rmed.2010.12.015.
100. Saint, S, Bent, S, Vittinghoff, E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. *JAMA.* 1995;273:957-60.
101. Puhan MA, Vollenweider D, Latshang T, Steurer J, Steurer-Stey C. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. *Respir Res.* 2007 Apr 4;8:30. [Erratum in: *Respir Res.* 2008;9:81].
102. Anthonen NR, Manfreda J, Warren CP, Warren CP, Herschfield ES, Harding GK, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med.* 1987;106:196-204.
103. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. *Chest.* 2000;117:1638-45.
104. Lieberman D, Shmarkov O, Gelfer Y, Varsavsky R, Lieberman DV. Prevalence and clinical significance of fever in acute exacerbations of chronic obstructive pulmonary disease. *Eur J Clin Microbiol Infect Dis.* 2003;22:75-8.